Latest News

(UroToday.com) There have been significant changes in the landscape of treatment of metastatic hormone-sensitive prostate cancer (mHSPC) over the last five years, beginning with the publication of the CHAARTED trial and STAMPEDE Arm C demonstrating improved overall survival for patients receiving docetaxel in addition to androgen deprivation therapy. Subsequently, in 2017, the LATITUDE trial and STAMPEDE […]

(UroToday.com) Prostate cancer has relatively low rates of response to immunotherapy such as immune checkpoint blockade relative to other types of cancer. Strategies to improve the immune response against advanced prostate cancer are under evaluation. Jason M. Redman, MD, presented data from the Quick Efficacy Seeking Trial, designed to rapidly evaluate the safety and efficacy of […]

(UroToday.com) The MANSMED trial was designed to investigate the impact of adding Metformin to androgen deprivation therapy in either high-risk localized prostate cancer or metastatic castration-sensitive prostate cancer. This is a randomized, single-blinded trial that includes patients regardless of a diagnosis of diabetes (though all patients had not taken metformin). Patients were randomized 1:1 to either […]

(UroToday.com) In this study, the authors present a retrospective analysis of the co-occurrence between actionable gene mutations and microsatellite instability-high status from next-generation sequencing of 20,296 tumors collected by 3D Medicines, a precision medicine company in China. The cohort is shown below. Fusions that were considered actionable include those involving ALK, RET, ROS1, FGFR1-4 and […]

(UroToday.com) At the 2020 European Society for Medical Oncology Virtual Congress (ESMO), Dr. Ben Tran presented AMG 160, a half-life extended, PSMA-targeted, bispecific T-cell engager (BiTE®) for patients with metastatic castration-resistant prostate cancer (mCRPC) (NCT03792841). Dr. Cora Sternberg then provided the invited discussant presentation of this new research in prostate immunotherapy.

– Cabozantinib in combination with atezolizumab demonstrated promising preliminary efficacy and a favorable safety profile in cohorts of patients with clear cell and non-clear cell renal cell carcinoma – Data presented during the European Society for Medical Oncology Virtual Congress 2020 San Francisco, CA (UroToday.com) — Exelixis, Inc. announced positive phase 1b clinical trial results for the combination of cabozantinib (CABOMETYX®) […]

(UroToday.com) Further therapies to improve patient outcomes in metastatic castration-resistant prostate cancer (mCRPC) are required as resistance to currently approved therapies invariably develops. Immunotherapy responses have been limited in mCRPC. Bispecific T-cell engagers are a novel approach to tumor immunotherapy (blinatumomab being the only currently approved BiTE therapy) which are targeted towards a tumor antigen as […]

(UroToday.com) There is an urgency to develop therapies with novel mechanisms of action to treat prostate cancers resistant to chemohormonal and radiation therapies. Unfortunately, to date, immune therapies have offered limited efficacy in patients with metastatic castration-resistant prostate cancer (mCRPC). More recently, there has been excitement regarding PSMA as a clinically validated therapeutic target in prostate […]

(UroToday.com) Prostate cancer screening guidelines for men with germline BRCA alterations are not well established. The one completed study in this space was the IMPACT (Identification of Men with a genetic Predisposition to prostate Cancer: Targeted screening in men at higher genetic risk and controls”1. This study, implemented before prostate MRI became routinely implemented, found that […]

(UroToday.com) The benefit of local therapy to the prostate in metastatic prostate cancer remains unclear. There was no survival benefit to local therapy across unselected patients with metastatic prostate cancer in the HORRAD and STAMPEDE trials, but unplanned subgroup analysis in the HORRAD trial suggested benefit in those with low-volume metastatic disease and planned subgroup […]